CVRx

CVRx Enterprise Value

The Enterprise Value (EV) of CVRx (CVRX) as of Oct 8, 2026 is 103.55 M USD. In the previous year, Enterprise Value (EV) was 73.08 M USD — a change of 41.69% (higher).

Enterprise Value

103.55 MUSD

YoY

41.69%

Last updated:

Enterprise Value (EV) of CVRx is 2025 103.55 M USD. Enterprise Value (EV) of CVRx was 2024 73.08 M USD. It decreases by 41.69% higher compared to the previous year.

The CVRx Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2019
123.00 M USD
Jan 1, 2020
89.93 M USD
Jan 1, 2021
-12.33 M USD
Jan 1, 2022
30.25 M USD
Jan 1, 2023
68.39 M USD
Jan 1, 2024
73.08 M USD
Jan 1, 2025
103.55 M USD
The CVRx Enterprise Value history
YEAREnterprise ValueYoY
103.55 MUSD+41.69%
73.08 MUSD+6.85%
68.39 MUSD+126.12%
30.25 MUSD-345.27%
-12.33 MUSD-113.71%
89.93 MUSD-26.89%
123.00 MUSD—
Access this data via the Eulerpool API

CVRx Stock analysis

What does CVRx do? CVRx Inc is a medical technology company that is revolutionizing the global market for treatment-resistant hypertension patients with its innovative "Baroreflex Activation Therapy" (BAT) system. The company was founded in 2001 and has its headquarters, development, manufacturing, and distribution facility in Minneapolis, Minnesota. With its innovative products and medical expertise, the company aims to become a global leader in medical research and development of apps and medical devices. The company was founded by Dr. Robert Kieval and his partner in medical research, Dr. Casey Cunningham. Together, they identified a potential treatment gap for patients who were unresponsive to existing methods or unable to receive appropriate therapy due to comorbidities. They decided to develop a novel technology that activates the body's natural regulatory system, the baroreflex system. With a clinical expert team in Minneapolis, they developed an implantable device connected to specific pressure zones in the neck through an electrode. The device artificially stimulates the baroreflex and regulates the blood pressure system. After many years of clinical tests and studies, the company received FDA approval in 2019. The company is now publicly listed, and its products are available worldwide. CVRx's business model is based on the research, development, production, and marketing of innovative medical devices and technologies. The focus is on improving patients' quality of life and advancing medical research. The products and therapies are distributed globally through contractual partners and subsidiaries. In addition to developing and marketing medical devices, the company conducts research to develop innovative diagnostic and therapeutic methods. The needs of patients and medical research are always the central focus. CVRx Inc specializes in the development and manufacture of implantable electronic devices for the treatment of patients with chronic cardiovascular diseases. The company's main product is the BAROSTIM NEO System, which is CE-certified in Europe. The system consists of two components: an implanted device and an external remote control. The device is surgically placed below the collarbone, and an electrode is inserted into a carotid artery. The remote control is used to regulate the electrical impulses delivered by the device to the carotid artery, activating the baroreflex system. Clinical studies have shown that BAT therapy is effective in lowering systolic blood pressure in patients with severe and persistent hypertension and can also have positive effects on heart failure patients. The company plans to use the BAROSTIM NEO System for other conditions, such as chronic kidney disease or sleep apnea. CVRx also invests in the development of mobile applications and software to support data analysis and patient monitoring. In summary, CVRx Inc is a medical technology company specialized in the development and manufacture of implantable electronic devices. The company is revolutionizing the global market for treatment-resistant hypertension patients with its Baroreflex Activation Therapy (BAT) system. The company focuses on improving patients' quality of life and advancing medical research. In addition to the BAROSTIM NEO System, the company conducts research to develop innovative diagnostic and therapeutic methods. CVRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CVRx stock

Enterprise Value (EV) of CVRx is 103.55 M USD in 2025.

Enterprise Value (EV) of CVRx changed from 73.08 M USD to 103.55 M USD, representing a 41.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) CVRx since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s CVRx with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — CVRx

All Key Metrics — CVRx